PharmaBoardroom

Biosimilar Uptake in Europe: Big Challenges; Bigger Rewards

Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving…

The Fight Against Superbugs: Properly Incentivising Antimicrobial…

BIO's Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global…

The US in 2020: Structural Constraints to Rein in Political…

Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to…

Tending the Garden of RWD via Project EHDEN: 21st Century Tools…

Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN's scope and purpose and highlights why greater collaboration on…

PharmaBoardroom Looks Ahead to 2020

PharmaBoardroom featured a wide range of developments in the life sciences industry in 2019, including a growing focus on China and the Asia Pacific…

10 Key Insights From PharmaBoardroom Contributors in 2019

2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics…

A New Approach to Rare Diseases in Canada

Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.…

A New Industrial Strategy for Europe: Win-Win for Both Economies…

The EFPIA's Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart. The…

Countering Hospital-Acquired Infections with a Culture of Safety

Becton Dickinson's Fiona Garín looks at the rise of Healthcare-Acquired Infections (HAIs) in Europe and how an industry-wide culture of safety needs…

180-Day Exclusivity: The Key Ingredient in Hatch-Waxman

The AAM's Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry…

Want to Change Healthcare? Coalitions are Key

Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption, data-driven demands and…

Three More Key Issues for Pharma: Regulatory Assertiveness,…

Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading…

Tagged with Opinion